Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated

Related Keywords

Columbus ,Ohio ,United States ,San Antonio ,Texas ,Paul Plourde ,Elizabeth Attias ,Monica Kozlowski ,Glenn Garmont ,Miriam Portman ,Simon Jenkins ,David Portman ,Barry Komm ,Ligand Pharmaceuticals Inc ,Nasdaq ,Society Lifestyle ,Healthcare Pharmaceuticals Industry ,Astrazeneca ,Parke Davis Pharmaceuticals ,Sermonix Pharmaceuticals Inc ,Henryb Gonzalez Convention Center ,Duke University ,Investor Relations Corporate Communications ,Quality Of Life Survey ,Pharmaceuticals Inc ,Antonio Breast Cancer Symposium ,Convention Center ,Life Survey ,Ligand Pharmaceuticals ,Anthony Wild ,Investor Relations Corporate ,Pharmaceuticals Announces Four Abstracts Accepted ,Antonio Breast Cancer ,Internet News Presswire ,Editorial Guidelines ,Sermonix ,Pharmaceuticals ,Announces ,Four ,Abstracts ,Accepted ,For ,Presentation ,Hat ,2022 ,San ,Antonio ,Breast ,Cancer ,Symposium ,